Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CMG1A46 in High grade B-cell lymphoma: NCT05987605 Clinical Landscape Report 2026
16 October 2026
NCT05987605 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Triple Negative Breast Cancer: NCT05989828 Clinical Landscape Report 2026
16 October 2026
NCT05989828 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Solid tumor: NCT05996445 Clinical Landscape Report 2026
16 October 2026
NCT05996445 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in B-Cell Lymphoma: NCT06002659 Clinical Landscape Report 2026
16 October 2026
NCT06002659 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Mediastinal large B-cell lymphoma: NCT06003179 Clinical Landscape Report 2026
16 October 2026
NCT06003179 clinical landscape for Mediastinal large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
GTAEXS-617 in Pancreatic adenocarcinoma: NCT05985655 Clinical Landscape Report 2026
16 October 2026
NCT05985655 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Azeliragon in Glioblastoma Multiforme: NCT05986851 Clinical Landscape Report 2026
16 October 2026
NCT05986851 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Famitinib Malate in Triple Negative Breast Cancer: NCT05999149 Clinical Landscape Report 2026
16 October 2026
NCT05999149 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HY-004 (Juventas) in High grade B-cell lymphoma: NCT06005649 Clinical Landscape Report 2026
16 October 2026
NCT06005649 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
APG-157 in Glioblastoma Multiforme: NCT06011109 Clinical Landscape Report 2026
16 October 2026
NCT06011109 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Renal Cell Carcinoma: NCT06004336 Clinical Landscape Report 2026
16 October 2026
NCT06004336 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RG-6540 in High grade B-cell lymphoma: NCT06014762 Clinical Landscape Report 2026
16 October 2026
NCT06014762 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.